15:55:16 <RRSAgent> RRSAgent has joined #hcls
15:55:16 <RRSAgent> logging to http://www.w3.org/2014/01/14-hcls-irc
15:55:22 <ericP> Zakim, this will be COI
15:55:22 <Zakim> I do not see a conference matching that name scheduled within the next hour, ericP
15:55:25 <ericP> Zakim, this will be hcls
15:55:25 <Zakim> ok, ericP; I see SW_HCLS()11:00AM scheduled to start in 5 minutes
15:56:11 <Zakim> SW_HCLS()11:00AM has now started
15:56:18 <Zakim> +ericP
15:58:54 <TimW> TimW has joined #HCLS
16:00:36 <Zakim> + +1.919.767.aaaa
16:00:51 <ericP> Zakim, aaaa is TimWilliams
16:00:51 <Zakim> +TimWilliams; got it
16:01:04 <Zakim> +Mike_Denny
16:01:22 <Zakim> +Kerstin_Forsberg
16:02:11 <charlie> charlie has joined #HCLS
16:02:23 <kerstin> kerstin has joined #hcls
16:03:24 <ericP> Zakim, code?
16:03:24 <Zakim> the conference code is 4257 (tel:+1.617.761.6200 sip:zakim@voip.w3.org), ericP
16:03:49 <Zakim> +charlie
16:04:49 <charlie_> charlie_ has joined #HCLS
16:05:14 <ericP> Zakim, who is here?
16:05:15 <Zakim> On the phone I see ericP, TimWilliams, Mike_Denny, Kerstin_Forsberg, charlie
16:05:15 <Zakim> On IRC I see charlie_, kerstin, TimW, RRSAgent, TallTed, egonw_, Zakim, ericP
16:06:08 <ericP> topic: FDA Therapeutic Area strawman
16:06:16 <ericP> scribenick: ericP
16:06:27 <ericP> -> http://www.w3.org/2013/12/FDA-TA/ strawman
16:08:10 <ericP> charlie_: FDA said the focus on the TA work is efficacy points
16:08:51 <ericP> ... obsevations connecting intervention and pathophysioly
16:09:07 <ericP> ... obs: normal, outcomes, endpoints
16:09:14 <kerstin> Charlie talking through http://www.w3.org/2013/12/FDA-TA/TA-MetaModel-cmap.png
16:09:28 <ericP> ... metamodel is the above model
16:10:57 <Sajjad> Sajjad has joined #hcls
16:11:23 <ericP> ericP: bottom-up abuse of the metamodel, coopted for base classes
16:11:53 <Zakim> +??P37
16:12:08 <ericP> Zakim, ??P37 is Sajjad
16:12:08 <Zakim> +Sajjad; got it
16:12:19 <ericP> -> http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(4)
16:14:28 <Zakim> +[IPcaller]
16:15:19 <ericP> Zakim, IPcaller is claude
16:15:20 <Zakim> +claude; got it
16:16:41 <ericP> http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2)
16:17:09 <Claude> Claude has joined #hcls
16:17:46 <ericP> http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2)
16:23:21 <ericP> Claude: i think of observations as quantitative measurements and the thing i do the make the observations
16:24:02 <ericP> ... unless obs really means the act of observing, and the result is captured elsewhere, this model is potentally confusing
16:24:21 <ericP> ... coulld separate the act of observing from the data observed
16:24:54 <ericP> charlie_: in early RIM, there was a separation. now Obs is a kind of Act with a code.
16:25:18 <ericP> ... RIM has substance administration etc.
16:26:03 <ericP> ... FDA cares about processes as measured by some generic idea of the value of the obs
16:26:14 <ericP> Claude: i'm working on models for CDS
16:27:01 <ericP> charlie_: FDA is not trying to feed CDS, instead just looking at the evidence around effectiveness of intervention
16:28:01 <ericP> Claude: we're looking at a CDS ontology, could we interop with this?
16:28:04 <ericP> charlie_: we asked that it all be sharable, but note that this will be narrow
16:29:15 <ericP> ericP: is the distinction useful in CDS?
16:29:49 <ericP> Claude: HL7's model for CDS is the Virtual Medical Record
16:32:00 <ericP> ... a CDS rule might look at a set of characteristics about a patient and fire off a diagnostic procedure
16:34:35 <ericP> Sajjad: have you written formal dens?
16:34:42 <ericP> charlie_: FDA knows they have to do it
16:34:54 <ericP> -> http://www.w3.org/2013/12/FDA-TA/ strawman
16:35:41 <Mike> Mike has joined #hcls
16:37:25 <ericP> ericP: can two people use variations of a ontology and get useful data interop
16:37:44 <ericP> http://www.w3.org/2014/Talks/0107-FDA-TA-egp/
16:37:50 <ericP> -> http://www.w3.org/2013/12/FDA-TA/ strawman
16:40:35 <ericP> charlie: expect ta-specific, ta-group (e.g. commonalities at organ level or systemic processes like inflamation), and pan-ta
16:41:03 <ericP> ... we need to show FDA that common semantics across TAs will be recognizable